Simon Dumesnil's Stock Option Award in Pasithea Therapeutics Corp.

Simon Dumesnil, a director of Pasithea Therapeutics Corp., was awarded 42,913 stock options on October 24, 2025, under the company's 2023 Stock Incentive Plan. The options, which grant the right to buy common stock at $0.715 per share, will fully vest on the one-year anniversary of the grant date, provided Dumesnil remains a director through that date. In the event of a Change in Control, the options will vest immediately. The options expire on October 23, 2035. This transaction was reported in a Form 4 filing with the SEC.